Digital Look

Welcome to Digital Look++,
you are not logged in

AstraZeneca (AZN)

Pharma and Biotech

13,930.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Sep-26	Q3	16,209.00	3,958.00	202.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-21	37,417.00	(265.00)	8.00¢	1,435.4	n/a	-97%	287.00¢	2.5%
31-Dec-22	44,351.00	2,501.00	212.00¢	70.0	0.0	+2,550%	290.00¢	2.0%
31-Dec-23	45,811.00	6,899.00	726.00¢	19.3	0.1	+242%	290.00¢	2.1%
31-Dec-24	54,073.00	8,691.00	454.00¢	30.5	n/a	-38%	310.00¢	2.2%
31-Dec-25	58,739.00	12,402.00	660.00¢	27.6	0.6	+45%	320.00¢	1.8%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-26	63,218.48	20,169.73	751.54p	18.5	0.4	+52%	249.37p	0.0%
31-Dec-27	67,236.88	22,271.47	841.95p	16.5	1.4	+12%	264.05p	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	1466.98	18.60	321.32	0.08

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.